Here are relevant reports on : ovulation-predictor-kits-market
-
High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030
Global high content screening market valued at $1.47B in 2024, reached $1.52B in 2025, and is projected to grow at a robust 7.5% CAGR, hitting $2.19B by 2030. Market growth in the Asia Pacific can be attributed to the increased pharmaceutical and biotechnology investments and the rising demand for personalized medicine.
- Published: April 2025
- Price: $ 4950
- TOC Available:
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market, valued at US$3.3 billion in 2022, stood at US$3.5 billion in 2023 and is projected to advance at a resilient CAGR of 10.6% from 2023 to 2028, culminating in a forecasted valuation of US$5.8 billion by the end of the period. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029
The global DNA diagnostics market, valued at US$12.3 billion in 2023, stood at US$13.3 billion in 2024 and is projected to advance at a resilient CAGR of 9.7% from 2024 to 2029, culminating in a forecasted valuation of US$21.2 billion by the end of the period. Growth in the market is primarily driven by the technological improvements in the DNA diagnostics industry and the growing need for personalized treatment and early disease diagnosis in developing nations. Also, the increased investments by healthcare-based companies are majorly contributing to growth of the market.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Virology Specimen Collection Market by Product (Viral Transport Media, Swabs, Blood Collection Kits, Specimen Collection Tubes), Sample Type (Blood, Cervical, Nasal, Nasopharyngeal, Throat, Oral), Region - Global Forecast to 2026
The global Virology Specimen Collection Market boasts a total value of $5.6 billion in 2021 and is projected to register a growth rate of -0.6% to reach a value of $5.4 billion by 2026. The major players operating in this market are Becton, Dickinson and Company (US), Quidel Corporation (US), Thermo Fisher Scientific, Inc. (US), Trinity Biotech (Ireland), Titan Biotech, Ltd. (India), Diasorin SA (Italy), Vircell S.L. (Spain), Copan Italia S.p.A. (Italy), Puritan Medical Products, Co. (Guilford, ME) and Hardy Diagnostics (US).
- Published: December 2021
- Price: $ 4950
- TOC Available:
-
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030
The global molecular cytogenetics market, valued at US$0.97 billion in 2024, stood at US$1.02 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2030, culminating in a forecasted valuation of US$1.43 billion by the end of the period. The market growth is fueled by increasing incidence of cancer & genetic disorders and rising usage of molecular cytogenetics in clinical pathology testing.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Urinalysis Market by Product (Consumables (Pregnancy & Fertility Kits, Dipsticks, Disposable, Reagents), Instruments (Automated, Semi-automated, PoC Analyzers)), Test Type (Biochemical, Sediment), Application (UTI, Diabetes) - Global Forecast to 2029
The global urinalysis market, valued at US$4.0 billion in 2023, stood at US$4.3 billion in 2024 and is projected to advance at a resilient CAGR of 9.6% from 2024 to 2029, culminating in a forecasted valuation of US$6.8 billion by the end of the period. Growth in this market is mainly driven by factors such as the increasing burden of urinary tract infections (UTIs), diabetes, and kidney & liver diseases and the increasing adoption of PoC tests.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
The global microbiome diagnostics market, valued at US$126 million in 2022, stood at US$146 million in 2023 and is projected to advance at a resilient CAGR of 15.5% from 2023 to 2028, culminating in a forecasted valuation of US$300 million by the end of the period. Market growth is driven by the rising incidence of chronic diseases, collaborative efforts between microbiome industry and academic institutes, and growing demand of personalized medicine.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
CRISPR Market by Offering (Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)), Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030
The global CRISPR market, valued at US$2.90 billion in 2024, stood at US$3.21 billion in 2025 and is projected to advance at a resilient CAGR of 11.2% from 2025 to 2030, culminating in a forecasted valuation of US$5.47 billion by the end of the period. The growing demand for CRISPR-based gene therapies, followed by advancements in CRISPR technology, and the rising government and private investments in CRISPR technology support the market growth. The development of new vaccines for the treatment of genetic diseases and the expansion of industrial and agricultural applications are presenting strong growth opportunities for CRISPR in the coming years.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Albumin & Creatinine Tests Market by Product (Analyzers, Cartridges (PoC, Tabletop), Dipsticks, Kits, Reagents), Type (Blood & Urine Creatinine, Urine Albumin, Glycated Albumin), Enduser (Hospital, Diagnostic & Research Labs) - Global Forecast to 2025
The global albumin & creatinine tests market growth is primed to transition from $987 million in 2020 to $2,103 million by 2025, showcasing a strong CAGR of 16.3%. The growth of this market is driven by the growing prevalence of kidney disorders and diseases, the rising adoption of POC diagnostics, and the increasing prevalence of chronic conditions.
- Published: January 2021
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
